Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Kimberly Clark Corp (KMB) vs GeneDx Holdings Corp (WGS) Price & Performance

Kimberly Clark CorpTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Kimberly Clark Corp vs GeneDx Holdings Corp — how do they compare? Kimberly Clark Corp trades at $108.46 (market cap $36.11B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Kimberly Clark Corp is far larger — about 14.8× GeneDx Holdings Corp's market cap, and Kimberly Clark Corp pays a 4.72% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

KMBWGS
Market Cap
$36.11B$2.44B
Sector
Consumer StaplesTechnology
52-Week High
$134.81$167.51
52-Week Low
$93.05$34.51
Enterprise Value
$41.67B$2.48B
Dividend Yield
4.72%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Kimberly Clark Corp

Kimberly-Clark (KMB) trades at $108.95, up 0.86% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, and the company cut its 2026 outlook due to challenges in China and softer consumer demand, as reported by Reuters on August 4, 2026.

The outlook is mixed; KMB offers a solid dividend yield and trades below the consensus price target of $113.20, but near-term headwinds from China and volatile shipments pose risks. Analyst sentiment is cautious with 61.29% hold ratings, reflecting balanced optimism for long-term value against short-term operational pressures.

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.

Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Kimberly Clark Corp

With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Read more on KMB

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS